Price History

Hover for the daily close. The dotted line marks the period open.

Compare MAZE with… →

MAZE Key Statistics

As of Sep 4, 2026

Trading

Open: $25.77
Previous Close: $25.87
Day's Range: 25.67–26.49
52-Week Range: 14.75–53.65
Volume: 273.30K

Valuation

Market Cap: $1.46B
P/E Ratio: unprofitable
P/S ratio: 72.80
EPS (ttm): −2.44

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$131.12M−351.04%
Profit margin: 0.00%
Shares Outstanding: 55.55M
1-Year Return: +74.27%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 551.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MAZE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−36.74%
2025	+159.75%

As of September 4, 2026.

MAZE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$131.12M	—
2024	$167.50M	$52.23M	31.2%
2023	$0.00	−$100.42M	—
2022	$0.00	−$114.94M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$142.90M	−$131.12M	—
2024	$167.50M	—	$57.59M	$52.23M	31.2%
2023	$0.00	—	−$98.55M	−$100.42M	—
2022	$0.00	—	−$111.03M	−$114.94M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MAZE Valuation vs Biotechnology Median

Median of 656 stocks

Metric	MAZE	Biotechnology median	vs median
P/S ratio	72.80	15.26	4.8x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Maze Therapeutics, Inc. (MAZE) at $1.46B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 141.

MAZE last closed at $26.21 on September 4, 2026. That is +$0.34 (+1.31%) against the previous close. Over the past 52 weeks the price has ranged from $14.75 to $53.65. The latest close sits 77.69% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $167.50M, that is a change of −100.00%. The same year closed with a net loss of $131.12M. Profit margin runs at 0%. Trailing earnings per share are −2.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 72.8 times revenue. On price-to-sales that is 4.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +74.27%. The stored price history starts on January 31, 2025, and the total return since then is +64.33%. Daily returns over the trailing 1 year annualize to a volatility of 83.25%.

Growth & Income

The record shows no dividend for MAZE.

So far in 2026 the price is −36.74%. The record holds one complete calendar year, 2025, which returned +159.75%.

Peer Comparison

Maze Therapeutics, Inc. (MAZE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Maze Therapeutics, Inc.	MAZE	$1.46B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Maze Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Visit website →

Maze Therapeutics, Inc. (MAZE) Stock Analysis